About Microba
Microba is a company based in Brisbane (Australia) founded in 2017 by Gene Tyson. Microba has raised $2.85 million across 3 funding rounds from investors including NIH, Macrogen and Sonic Healthcare. Microba has completed 1 acquisition, including Invivo Healthcare. Microba offers products and services including MetaPanel, MetaXplore, Analysis Platform, Discovery Platform, and Therapeutic Platform. Microba operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Brisbane, Australia
- Founders Gene Tyson
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Microba Life Sciences Limited
-
Annual Revenue
$10.23 M (USD)29.6as on Jun 30, 2025
-
Net Profit
-$9.76 M (USD)25.07as on Jun 30, 2025
-
EBITDA
-$13.18 M (USD)15.83as on Jun 30, 2025
-
Total Equity Funding
$2.85 M (USD)
in 3 rounds
-
Latest Funding Round
$9.35 M (USD), Post-IPO
Jun 23, 2025
-
Investors
NIH
& 2 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Microba
Microba is a publicly listed company on the ASX with ticker symbol MAP in Australia, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Microba
Microba offers a comprehensive portfolio of products and services, including MetaPanel, MetaXplore, Analysis Platform, Discovery Platform, and Therapeutic Platform.
Next-generation test for gastrointestinal health diagnostics.
Platform for microbiome exploration and health insights.
End-to-end solution for microbiome data processing.
Databank for identifying microbiome-disease relationships.
System for developing microbial leads for chronic diseases.
People of Microba
Unlock access to complete
Unlock access to complete
Funding Insights of Microba
Microba has successfully raised a total of $2.85M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $9.35 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Microba
Microba has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include NIH, Macrogen and Sonic Healthcare.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked | |
|
Next-generation sequencing and genomics services are provided globally.
|
Locked | Locked | Locked | |
|
Chain of pathology and radiology labs
|
Locked | Locked | Locked |
Investor details for Microba
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Microba
Microba has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Invivo Healthcare.
Investment portfolio details for Microba
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of microbiome tests and supplements to support human microbiome
|
Locked | Locked | 2007 | Locked |
Complete acquisition details for Microba
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Microba
Detailed financials for Microba
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Microba Comparisons
Peer comparison for Microba
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Microba
Microba operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Provider of cell therapies to treat cancer and hematologic conditions
|
Detailed competitors of Microba
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Microba
Complete news archive for Microba
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Microba
Microba was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Microba is headquartered in Brisbane, Australia. It is registered at Brisbane, Queensland, Australia.
Blake Wills is the current CEO of Microba.
Microba is a funded company, having raised a total of $2.85M across 3 funding rounds to date.
Annual revenue of Microba is $10.23M as on Jun 30, 2025.
Microba was founded in 2017 in Brisbane, Australia, within the biotechnology sector focused on microbiome research. A drug discovery platform is operated, where human data and informatics methods are applied to link microbial genotypes with human phenotypes. Therapeutic pipelines are advanced for inflammatory bowel disease and immuno-oncology applications, supporting targeted medical advancements.
Microba's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Microba offers MetaPanel, MetaXplore, Analysis Platform, Discovery Platform, and Therapeutic Platform.
Yes, Microba is publicly traded on ASX under the ticker symbol MAP.
Microba has made 1 acquisition, including Invivo Healthcare.
Microba has 3 investors. Key investors include NIH, Macrogen, and Sonic Healthcare.
The ticker symbol of Microba is MAP on ASX.